Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Finding the right balance between safety and returns isn’t easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could offer consistent gains and two that may not keep up.
Two Stocks to Sell:
Janus (JBI)
Rolling One-Year Beta: 0.85
Standing out with its digital keyless entry into self-storage room technology, Janus (NYSE: JBI) is a provider of easily accessible self-storage solutions.
Why Does JBI Fall Short?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Sales are projected to be flat over the next 12 months and imply weak demand
- Earnings per share have contracted by 13.8% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance
At $9.82 per share, Janus trades at 7.1x forward EV-to-EBITDA. To fully understand why you should be careful with JBI, check out our full research report (it’s free).
Jazz Pharmaceuticals (JAZZ)
Rolling One-Year Beta: 1.01
Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.
Why Should You Dump JAZZ?
- Annual revenue growth of 4.2% over the last two years was below our standards for the healthcare sector
- Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 25.4 percentage points
- Earnings per share fell by 12.1% annually over the last five years while its revenue grew, partly because it diluted shareholders
Jazz Pharmaceuticals’s stock price of $111.23 implies a valuation ratio of 5.8x forward P/E. Dive into our free research report to see why there are better opportunities than JAZZ.
One Stock to Buy:
Celsius (CELH)
Rolling One-Year Beta: 0.44
With its proprietary MetaPlus formula as the basis for key products, Celsius (NASDAQ: CELH) offers energy drinks that feature natural ingredients to help in fitness and weight management.
Why Are We Bullish on CELH?
- Impressive 50.7% annual revenue growth over the last three years indicates it’s winning market share
- Earnings growth has massively outpaced its peers over the last three years as its EPS has compounded at 82.2% annually
- ROIC punches in at 34.2%, illustrating management’s expertise in identifying profitable investments, and its returns are growing as it capitalizes on even better market opportunities
Celsius is trading at $51.57 per share, or 50.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
